The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 20, 2010
Filed:
May. 13, 2005
Stephen D. Goble, Edison, NJ (US);
Sander G. Mills, Scotch Plains, NJ (US);
Lihu Yang, Edison, NJ (US);
Alexander Pasternak, Princeton, NJ (US);
Celine Bonnefous, San Diego, CA (US);
Theodore M Kamenecka, Palm Beach Gardens, FL (US);
Jean-michel Vernier, Laguna Niguel, CA (US);
John H. Hutchinson, LaJolla, CA (US);
Essa HU, Camarillo, CA (US);
Steven Govek, San Diego, CA (US);
Stephen D. Goble, Edison, NJ (US);
Sander G. Mills, Scotch Plains, NJ (US);
Lihu Yang, Edison, NJ (US);
Alexander Pasternak, Princeton, NJ (US);
Celine Bonnefous, San Diego, CA (US);
Theodore M Kamenecka, Palm Beach Gardens, FL (US);
Jean-Michel Vernier, Laguna Niguel, CA (US);
John H. Hutchinson, LaJolla, CA (US);
Essa Hu, Camarillo, CA (US);
Steven Govek, San Diego, CA (US);
Merck & Co., Inc., Rahway, NJ (US);
Abstract
Cyclopentyl compounds linked to a benzoxazinyl group through an amido moiety utilizing the ring nitrogen of the benzoxazine, and further substituted with a heterocyclic moiety, such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions.